Continuous Manufacturing

FROM BATCH TO CONTINUOUS

Continuous manufacturing is a method for manufacturing pharmaceutical products from end-to-end on a single, always-on uninterrupted production line. The aim is to eliminate batch inefficiencies that result in process stoppages, long hold times, and sub-optimal facility utilization.

Traditional pharmaceutical manufacturing is done in batches, where a batch is a specific quantity of a drug produced through a multi-step process. While batch production is a tested manufacturing method utilized by the majority of pharmaceutical companies today, the process can be slow and inefficient, requiring frequent stoppages for quality testing, and physical product transfer between unit operations (and sometimes between facilities).

To streamline production, continuous manufacturing combines the full manufacturing stream into a single, fully integrated flow, enabling faster speed to market, better process control, smaller factories and environmental footprints, more consistent product quality, modular manufacturing, and lower capital and operating costs.

Continuous processes can be fully end-to-end continuous, a hybrid of batch and continuous, or individual continuous operations retrofitted into a batch process. Selection of the approach is guided by an evaluation of the product, process, equipment, regulations, enterprise readiness, technology availability, market demand, and volume and/or value of the product.

Repligen solutions help overcome key challenges in continuous manufacturing, with hands-on process and implementation consultation from global Field Applications Specialists.

Speak to an expert

Perfusion Cell Culture

Perfusion, a cornerstone of upstream continuous bioprocessing, has been practiced since the 1980s to maximize facility utilization, expand process flexibility and minimize costs. Today, novel cell retention devices and single-use technologies, with sophisticated control logic, simplify implementation.

N-1 Perfusion

A form of seed train intensification, N-1 perfusion refers to the intensification of cell growth in the seed train step (N-1) before the production bioreactor (N), achieving a more rapid and robust process while maintaining an existing Fed-Batch based production scheme.

Seed Train Intensification

Seed train intensification aims to generate ultra high-density cell cultures at optimal points during cell expansion using a robust cell retention device prior to the inoculation of the production bioreactor.

XCell® ATF Systems

Simplify and intensify upstream bioprocessing. The XCell® ATF System, in single-use or stainless steel format, delivers high cell retention. High impact upstream solutions include N-1 perfusion, high productivity harvest, long-term perfusion and seed train intensification.

CTech™ FlowVPX® System

In-line GMP testing

Designed to meet the rigors of regulatory GMP requirements, the new CTech FlowVPX® spectrophotometer system offers reliable real-time results with integrated ease for concentration measurements during every stage of the downstream GMP process.

Customer First.

Support is part of the Repligen DNA. Our goal is to provide exceptional customer experience, and to support the efficient and successful adoption and implementation of all Repligen products and services.

  • Field Application Support
  • Customer Service
  • Field Service Engineers

Have a question?